Skip to main content
main-content

Medicine Matters branded image Welcome

We provide news, expert interviews, and educational resources to help you keep up with the latest developments in oncology

Panel discussion

RET fusion-positive NSCLC treatment

RET fusion-positive NSCLC treatment, Stephen Liu

This content is intended only for healthcare providers and was made possible by educational funding provided by F. Hoffmann-La Roche Ltd.

New additions to the Adis Journal Club – January update

Targeted Oncology Journal

Browse January's selection of peer-reviewed articles from the Adis journal portfolio. Curated by the editors and updated monthly. These papers highlight topical research and reviews for the benefit of Medicine Matters readers.

Interview

RET fusion-positive NSCLC treatment

ARROW study - Stephen Liu

This content is intended only for healthcare providers and was made possible by educational funding provided by F. Hoffmann-La Roche Ltd.

IN FOCUS | COVID-19 & cancer

12-01-2022 | COVID-19 | News

Antibody response to COVID-19 vaccine strengthened after third dose in cancer patients

Research from three countries adds support for the use of a booster dose of vaccines against SARS-CoV-2 in people with cancer, especially those undergoing active anticancer treatment.

New additions to the Adis Journal Club

A selection of topical peer-reviewed articles from the Adis journals, curated by the editors.

Stay informed with Medicine Matters

Get the latest developments in breast, lung, & GU cancers delivered straight to your inbox

IN FOCUS | Breast cancer

14-12-2021 | SABCS 2021 | Conference coverage | News

PADA-1 shows clinical utility of blood ESR1 mutation monitoring

Women with hormone receptor-positive, HER2-negative metastatic breast cancer benefit from switching from an aromatase inhibitor to fulvestrant in palbociclib combination therapy when an ESR1 mutation is detected without disease progression, phase 3 PADA-1 trial data show.

IN FOCUS | Lung & thoracic cancers

12-11-2021 | Non-small-cell lung cancer | News

EGFR-positive NSCLC recurrence patterns explored

People with EGFR-positive non-small-cell lung cancer may benefit from individualized risk-profiling, say researchers who observed a high recurrence risk following resection but also identified a subgroup that may be cured without adjuvant osimertinib.

  • » This content is intended only for healthcare providers and was made possible by educational funding provided by F. Hoffmann-La Roche Ltd.

IN FOCUS | Genitourinary cancers

16-12-2021 | Immunotherapy | News

HLA-A*03 shows potential as a biomarker for ICI response

The risk for disease progression or death increases with HLA-A*03 allele count in people undergoing immune checkpoint inhibitor therapy for cancer, irrespective of tumor type and agent used, research suggests.

Podcasts

Interviews with clinical experts on cancer patient care

Image Credits